Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1228582#aggregation> ?p ?o. }
Showing items 1 to 56 of
56
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B257284.
- aggregation creator B257285.
- aggregation creator B257286.
- aggregation creator B257287.
- aggregation creator B257288.
- aggregation creator B257289.
- aggregation creator B257290.
- aggregation creator B257291.
- aggregation creator B257292.
- aggregation creator B257293.
- aggregation creator B257294.
- aggregation creator B257295.
- aggregation creator B257296.
- aggregation creator B257297.
- aggregation creator B257298.
- aggregation creator B257299.
- aggregation creator B257300.
- aggregation creator B257301.
- aggregation creator B257302.
- aggregation creator B257303.
- aggregation creator B257304.
- aggregation creator B257305.
- aggregation creator B257306.
- aggregation creator B257307.
- aggregation creator B257308.
- aggregation creator person.
- aggregation date "2008".
- aggregation format "application/pdf".
- aggregation hasFormat 1228582.bibtex.
- aggregation hasFormat 1228582.csv.
- aggregation hasFormat 1228582.dc.
- aggregation hasFormat 1228582.didl.
- aggregation hasFormat 1228582.doc.
- aggregation hasFormat 1228582.json.
- aggregation hasFormat 1228582.mets.
- aggregation hasFormat 1228582.mods.
- aggregation hasFormat 1228582.rdf.
- aggregation hasFormat 1228582.ris.
- aggregation hasFormat 1228582.txt.
- aggregation hasFormat 1228582.xls.
- aggregation hasFormat 1228582.yaml.
- aggregation isPartOf urn:issn:0028-4793.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Sorafenib in advanced hepatocellular carcinoma".
- aggregation abstract "Background No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. Methods In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. Results At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. Conclusions In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.".
- aggregation authorList BK532891.
- aggregation endPage "390".
- aggregation issue "4".
- aggregation startPage "378".
- aggregation volume "359".
- aggregation aggregates 1228614.
- aggregation isDescribedBy 1228582.
- aggregation similarTo LU-1228582.